Wahl Miriam L, Moser Tammy L, Pizzo Salvatore V
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Recent Prog Horm Res. 2004;59:73-104. doi: 10.1210/rp.59.1.73.
Many diseases have abnormal quality and/or quantity of vascularization as a characteristic feature. Cancer cells elicit the growth of new capillaries during neovascularization in a process termed angiogenesis. In diabetics, pathologic angiogenesis in various tissues is a clinical feature of many common complications. Therefore, the diabetic cancer patient warrants special consideration and extra care in the design of anti-angiogenic treatments without adverse side effects. Some treatment regimens that look promising in vitro, in animal models, or in early clinical trials may be contra-indicated for diabetics. This chapter will review the common complications of diabetes, with emphasis on the angiogenic pathology. Recent research related to the mechanism of action and basis for specificity of the anti-angiogenic peptide, angiostatin, will be the focus. The aim is to shed light on areas in which more research is needed with respect to angiostatin and other anti-angiogenic agents and the microenvironmental conditions that affect their activities, in order to develop improved therapeutic strategies for diabetic cancer patients.
许多疾病都具有血管形成的质量和/或数量异常这一特征。癌细胞在新血管形成过程中引发新毛细血管的生长，这一过程称为血管生成。在糖尿病患者中，各种组织中的病理性血管生成是许多常见并发症的临床特征。因此，在设计无不良副作用的抗血管生成治疗方案时，糖尿病癌症患者需要特别考虑和格外护理。一些在体外、动物模型或早期临床试验中看起来有前景的治疗方案可能对糖尿病患者是禁忌的。本章将回顾糖尿病的常见并发症，重点是血管生成病理学。抗血管生成肽血管抑素的作用机制和特异性基础的最新研究将是重点。目的是阐明在血管抑素和其他抗血管生成药物以及影响其活性的微环境条件方面需要更多研究的领域，以便为糖尿病癌症患者制定改进的治疗策略。
